Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.200 UNCHANGED
Streaming Delayed Price Updated: 10:27 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,831
Open 1.210
Bid (Size) 1.190 (4)
Ask (Size) 1.200 (1)
Prev. Close 1.200
Today's Range 1.170 - 1.210
52wk Range 0.9801 - 19.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Full Year 2024 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-86.2%
-86.2%
1 Month
-31.8%
-31.8%
3 Month
-74.8%
-74.8%
6 Month
-73.3%
-73.3%
1 Year
-92.6%
-92.6%

More News

Read More
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
Monday's pre-market session: top gainers and losers
Via Chartmill
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
From Traws Pharma, Inc.
Via GlobeNewswire
Thursday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Via Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Lower; Dow Tumbles 600 Points
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gold Moves Lower, Rumble Shares Jump
Via Benzinga
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November
Via Benzinga
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results
Via Benzinga
US Stocks Mixed, Dow Tumbles 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Traws Pharma, Inc. - Common Stock publicly traded?
Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
What exchange does Traws Pharma, Inc. - Common Stock trade on?
Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
What is the current price of Traws Pharma, Inc. - Common Stock?
The current price of Traws Pharma, Inc. - Common Stock is 1.200
When was Traws Pharma, Inc. - Common Stock last traded?
The last trade of Traws Pharma, Inc. - Common Stock was at 05/22/25 10:27 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.